Christopher Sarchi
Net worth: 2 M $ as of 31/05/2026
Net worth: 2 M $ as of 31/05/2026
Christopher Sarchi is currently Chief Commercial Officer at Bicara Therapeutics, Inc. since 2026 and Chief Commercial Officer at Replimune Group, Inc. since 2022.
Former positions include Director-Oncology Regional Sales at Genentech, Inc. from 2010 to 2013 and Head-Commercial Oncology US Region at Sanofi.
Education includes undergraduate studies at the University of Maine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/06/2026 | 180,962 ( 0.23% ) | 2 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Corporate Officer/Principal | 01/12/2022 |
| BICARA THERAPEUTICS INC. | Corporate Officer/Principal | 08/05/2026 |
| Companies | Position | End |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/01/2013 |
| SANOFI | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
University of Maine
University of Maine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Select your edition
All financial news and data tailored to specific country editions